Systemic sclerosis & Raynaud's
Prevalence and clinical relevance of systematically tested antimitochondrial antibodies in systemic sclerosis
Authors' conclusion
In our cohort of SSc patients systematically screened for autoantibodies, we found a high prevalence of AMA and identified a novel putative association with GI vascular involvement, which warrants confirmation in independent studies.
Study context
- Population
- Consecutive systemic sclerosis (SSc) patients followed at a referral centre (20% dcSSc, 33% ILD, 7.3% PAH; 51% anticentromere, 29% anti-topoisomerase I, 12% anti-RNA polymerase III)
- Participants
- 165 patients
- Exposure
- Antimitochondrial antibodies (AMA)-positive vs AMA-negative SSc patients
- AMA-positiven = 37
- Outcome
- Prevalence and clinical relevance of AMA in SSc
Methodological detailsconsecutive patients, referral centre
- Consecutive patients
- Referral centre
Main finding
As reported in the abstract
AMA prevalence
AMA-positive
22%
37
Observational data: associations, not effects.
Further findings
Gastrointestinal (GI) vascular involvement
| OR (95% CI) | P value | ||
|---|---|---|---|
| AMAIndependently from PBC or symptoms of SSc-GI involvement | 13.3 (2.53–95.0) | P = 0.002 | |
| 0.050.21520Odds ratio (log scale) |
Gastric antral vascular ectasia
| OR (95% CI) | P value | ||
|---|---|---|---|
| AMAIndependently from PBC or symptoms of SSc-GI involvement | 7.99 (1.05–72.5) | P = 0.045 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Prevalence and clinical relevance of systematically tested antimitochondrial antibodies in systemic sclerosis. Arthritis Res Ther. Published 19 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →